KScan™, the phosphoproteomics platform developed by Kinomica’s founders, has the potential to predict patient responses to targeted therapies with greater accuracy than currently possible.

KScan™ directly measures intracellular kinase and cell-signalling pathway activity in cells and tissues and combines the phosphoproteomics readout with innovative computational (including machine-learning) algorithms and high-quality data to reveal drug molecular efficacy, mechanisms of action and therapeutic resistance; identify and validate new biomarkers; inform clinical and diagnostic decision-making; and identify novel and/or alternative drug targets and therapies.

KScan™ offering can be tailored to provide a range of services to meet specific customer needs and is being developed further as a companion diagnostic technology to guide physicians in the selection of effective treatment for each individual patient, facilitating enhanced precision medicine.